Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript

Richard Ramanius: Yes. I think there’s some interesting projects you have. And well, my last question was, do you have any policy for takeover bids because it’s slips easy to remind when you see the investments that MSD has made logical steps that might be to try to make an acquisition?

Christian Kanstrup: Yes, of course, we can’t comment upon any question like that. If something relevant is to be communicated, of course, we will communicate that.

Operator: Thank you. We will now take our next question. Please stand by. And the next question comes from the line of Ahu Demir from Ladenburg Thalmann. Please go ahead. Your line is now open.

Ahu Demir: I just wanted to ask one more question regarding the outstanding debt. What is the current debt on the financial growth?

Christian Kanstrup: And I’m very happy to pass that question straight on to our CFO, but I can say it’s an EIB loan.

Jesper Nissen: So basically, our debt structure is pretty similar. We have an EIB loan, which is of $7 million, and it has an expiry date of Q1 2028.

Operator: As there are no further questions, I would like to hand back to Christian Kanstrup for any closing remarks. Please go ahead.

Christian Kanstrup: Thank you so much. And I just want to say, thank you to all of you for all the relevant and good questions, and thank you for listening in. We are excited about what has happened over the past several months here and equally excited about what’s to come for 2024, and we are looking forward to keeping you updated on that. So, thank you so much for listening in.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect. Speakers, please stand by.